Form 4: NHI Director Colden Granted Restricted Stock

National Health Investors director Tracy M.J. Colden received a grant of 1,268 shares of restricted common stock, which will vest in March 2027.

Summary

• Tracy M.J. Colden, a director of National Health Investors Inc. (NHI), was granted 1,268 shares of common stock.
• The transaction occurred on March 3, 2026.
• This grant represents restricted stock with a vesting date of March 3, 2027.
• Vesting is contingent upon Ms. Colden's continued service as a director through the vesting date.
• Following this transaction, Ms. Colden beneficially owns 12,858 shares of NHI common stock.
• The acquisition price for these restricted shares was $0, typical for a grant.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a slightly positive development, as it strengthens the alignment of a director's interests with long-term shareholder value through equity compensation.

Positives

• The restricted stock grant aligns the director's interests with those of shareholders, as the value of the grant is tied to the company's stock performance.
• The vesting schedule encourages long-term commitment and continued service from the director.

Negatives

• The issuance of new shares, even restricted, can result in minor dilution for existing shareholders, though 1,268 shares is a very small amount relative to NHI's total outstanding shares.

Risks

• The value of the restricted stock is subject to the future market price of NHI common stock.
• The director's ability to fully realize the value of the grant is contingent on continued service until March 3, 2027.

Future Outlook

The restricted stock grant is set to vest in full on March 3, 2027, provided Tracy M.J. Colden continues her service as a director of National Health Investors Inc. until that date.

Industry Context

StockSavvy.ai notes that restricted stock grants are a common form of equity compensation for directors and executives across various industries, including healthcare REITs like National Health Investors. This practice is generally viewed as a positive for corporate governance as it ties a director's personal financial interests to the long-term performance of the company, aligning them with shareholder value creation.

Comparison to Industry Standards

• StockSavvy.ai observes that granting restricted stock to directors is a standard practice in corporate compensation structures, similar to how other healthcare REITs such as Ventas (VTR) or Welltower (WELL) might compensate their non-employee directors.
• The vesting period of one year is also a common structure for such grants, aiming to retain directors and incentivize sustained performance.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor potential dilution from the issuance of shares, but improved alignment of director interests with shareholder value.
• Director (Tracy M.J. Colden): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• Continued service of Tracy M.J. Colden as a director until March 3, 2027, for the restricted stock to vest.

Key Dates

Keywords

National Health Investors, NHI, Tracy M.J. Colden, Director, Restricted Stock, Stock Grant, Insider Transaction, Form 4, Equity Compensation, Corporate Governance